NCT01594437View on ClinicalTrials.gov

Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

March 31, 2013

Conditions
Cytomegalovirus Infections
Interventions
BIOLOGICAL

TCN-202

Human monoclonal neutralizing antibody that recognizes a broadly conserved functional epitope on HCMV. One or two doses will be administered by intravenous infusion.

BIOLOGICAL

Placebo

One or two doses administered by intravenous infusion.

Trial Locations (1)

21201

SNBL Clinical Pharmacology Center, Baltimore

All Listed Sponsors
lead

Theraclone Sciences, Inc.

INDUSTRY

NCT01594437 - Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody | Biotech Hunter | Biotech Hunter